VTRS
Viatris Inc.
Price Chart
Latest Quote
$17.29
-0.04 (-0.23%)
Current Price
| Previous Close | $17.33 |
| Open | $17.34 |
| Day High | $17.67 |
| Day Low | $17.23 |
| Volume | 9,398,774 |
Stock Information
| Quarterly Dividend / Yield | $0.48 / 2.78% |
| Shares Outstanding | 1.16B |
| Quarterly Dividend Yield | 2.78% |
| Quarterly Dividend | $0.48 |
| Total Debt | $14.61B |
| Cash Equivalents | $2.40B |
| Revenue | $14.56B |
| Net Income | $-296.50M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $20.14B |
| EPS (TTM) | $-0.30 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $32.34B |
| Sales | $14.56B |
| Income | $-296.50M |
| Book/sh | $12.59 |
| Cash/sh | $2.06 |
| Employees | 30K |
Financial Ratios
| Quick Ratio | 0.90 |
| Current Ratio | 1.60 |
| Debt/Eq | 99.67 |
Returns & Margins
| ROA | 2.31% |
| ROE | -1.96% |
| Gross Margin | 39.82% |
| Operating Margin | 6.78% |
| Profit Margin | -2.04% |
Ownership
| Insider Ownership | 0.31% |
| Institutional Ownership | 88.22% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 6.49 |
| PEG | 0.15 |
| P/S | 1.38 |
| P/B | 1.37 |
Analyst Data
| Recommendation | buy |
| Target Price | $17.81 |
Technical Indicators
| SMA20 | $16.34 |
| SMA50 | $16.32 |
| SMA200 | $13.42 |
| RSI | 63.79 |
| ATR | 0.4721 |
| Shares Float | 1.16B |
| Short Float | 4.13% |
| Short Ratio | 4.83 |
| Volatility | 0.90 |
| Rel Volume | 0.93 |
Performance History
| Week | +6.27% |
| Month | +7.79% |
| Quarter | +24.32% |
| 6 Months | +33.58% |
| YTD | +40.98% |
| Year | +97.92% |
| 3 Years | +92.16% |
| 5 Years | +49.11% |
| 10 Years | -52.80% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $17.29 | 9,520,700 |
| 2026-07-16 | $17.33 | 9,478,700 |
| 2026-07-15 | $16.68 | 7,965,500 |
| 2026-07-14 | $16.31 | 9,320,600 |
| 2026-07-13 | $16.39 | 5,843,700 |
| 2026-07-10 | $16.27 | 7,928,300 |
| 2026-07-09 | $16.34 | 9,207,400 |
| 2026-07-08 | $16.66 | 8,683,500 |
| 2026-07-07 | $16.96 | 9,803,200 |
| 2026-07-06 | $16.80 | 11,422,100 |
| 2026-07-02 | $16.70 | 9,040,800 |
| 2026-07-01 | $16.18 | 13,488,300 |
| 2026-06-30 | $15.88 | 10,545,200 |
| 2026-06-29 | $16.23 | 8,986,900 |
| 2026-06-26 | $16.33 | 12,849,200 |
| 2026-06-25 | $16.07 | 8,413,400 |
| 2026-06-24 | $15.93 | 9,105,000 |
| 2026-06-23 | $15.75 | 8,811,000 |
| 2026-06-22 | $15.38 | 12,531,000 |
| 2026-06-18 | $15.37 | 22,642,100 |
About Viatris Inc.
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
đ° Latest News
Financial Stocks Rally To New Highs. JPMorgan Is One Of Them.
Investor's Business Daily âĸ 2026-07-17T19:49:52Z
Mylan to sell up to $363 million stake in India's Biocon, term sheet shows
Reuters âĸ 2026-07-13T13:43:27ZVTRS or DHR: Which Is the Better Value Stock Right Now?
Zacks âĸ 2026-07-09T15:40:04Z
Should Value Investors Buy Viatris (VTRS) Stock?
Zacks âĸ 2026-07-09T13:40:05Z
3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now
24/7 Wall St. âĸ 2026-07-07T17:19:51Z
Should Viatrisâ Japan IgA Nephropathy Win and New Loan Shape VTRS Investorsâ Next Move?
Simply Wall St. âĸ 2026-07-06T09:09:06Z
Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results
Insider Monkey âĸ 2026-07-05T22:48:32Z
Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now
Insider Monkey âĸ 2026-07-05T13:04:13Z
Viatris (VTRS) is a Great Momentum Stock: Should You Buy?
Zacks âĸ 2026-07-02T16:00:03Z
Theravance Stock Down 3% After Zymeworks Announces Buyout
Zacks âĸ 2026-06-30T12:54:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $9,286,400,000 | $9,115,700,000 | $8,988,300,000 | $9,765,700,000 |
| Cost Of Revenue | $9,286,400,000 | $9,115,700,000 | $8,988,300,000 | $9,765,700,000 |
| Total Revenue | $14,299,900,000 | $14,739,300,000 | $15,426,900,000 | $16,262,700,000 |
| Operating Revenue | $23,732,900,000 | $24,905,200,000 | $25,693,100,000 | $27,662,100,000 |
| Expenses | ||||
| Interest Expense | $471,300,000 | $550,000,000 | $573,100,000 | $592,400,000 |
| Total Expenses | $14,046,400,000 | $14,029,000,000 | $13,863,500,000 | $14,607,000,000 |
| Other Income Expense | $-3,447,200,000 | $-783,500,000 | $-787,400,000 | $1,749,900,000 |
| Other Non Operating Income Expenses | $-530,600,000 | $-83,300,000 | $9,800,000 | $1,790,700,000 |
| Net Non Operating Interest Income Expense | $-471,300,000 | $-550,000,000 | $-573,100,000 | $-592,400,000 |
| Interest Expense Non Operating | $471,300,000 | $550,000,000 | $573,100,000 | $592,400,000 |
| Operating Expense | $4,760,000,000 | $4,913,300,000 | $4,875,200,000 | $4,841,300,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,514,900,000 | $-634,200,000 | $54,700,000 | $2,078,600,000 |
| Net Interest Income | $-471,300,000 | $-550,000,000 | $-573,100,000 | $-592,400,000 |
| Normalized Income | $-717,880,600 | $-81,042,000 | $684,488,000 | $2,108,751,200 |
| Net Income From Continuing And Discontinued Operation | $-3,514,900,000 | $-634,200,000 | $54,700,000 | $2,078,600,000 |
| Total Operating Income As Reported | $-2,663,100,000 | $10,100,000 | $766,200,000 | $1,614,900,000 |
| Net Income Common Stockholders | $-3,514,900,000 | $-634,200,000 | $54,700,000 | $2,078,600,000 |
| Net Income | $-3,514,900,000 | $-634,200,000 | $54,700,000 | $2,078,600,000 |
| Net Income Including Noncontrolling Interests | $-3,514,900,000 | $-634,200,000 | $54,700,000 | $2,078,600,000 |
| Net Income Continuous Operations | $-3,514,900,000 | $-634,200,000 | $54,700,000 | $2,078,600,000 |
| Pretax Income | $-3,665,000,000 | $-623,200,000 | $202,900,000 | $2,813,200,000 |
| Special Income Charges | $-2,916,600,000 | $-700,200,000 | $-797,200,000 | $-40,800,000 |
| Operating Income | $253,500,000 | $710,300,000 | $1,563,400,000 | $1,655,700,000 |
| Gross Profit | $5,013,500,000 | $5,623,600,000 | $6,438,600,000 | $6,497,000,000 |
| Per Share | ||||
| Diluted EPS | $-3.00 | $-0.53 | $0.05 | $1.71 |
| Basic EPS | $-3.00 | $-0.53 | $0.05 | $1.71 |
| Other | ||||
| Tax Effect Of Unusual Items | $-119,580,600 | $-147,042,000 | $-167,412,000 | $-10,648,800 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $2,521,200,000 | $3,520,200,000 | $4,313,700,000 | $6,474,000,000 |
| Total Unusual Items | $-2,916,600,000 | $-700,200,000 | $-797,200,000 | $-40,800,000 |
| Total Unusual Items Excluding Goodwill | $-2,916,600,000 | $-700,200,000 | $-797,200,000 | $-40,800,000 |
| Reconciled Depreciation | $2,798,300,000 | $2,893,200,000 | $2,740,500,000 | $3,027,600,000 |
| EBITDA (Bullshit earnings) | $-395,400,000 | $2,820,000,000 | $3,516,500,000 | $6,433,200,000 |
| EBIT | $-3,193,700,000 | $-73,200,000 | $776,000,000 | $3,405,600,000 |
| Diluted Average Shares | $1,170,700,000 | $1,193,300,000 | $1,206,900,000 | $1,217,400,000 |
| Basic Average Shares | $1,170,700,000 | $1,193,300,000 | $1,200,300,000 | $1,212,100,000 |
| Diluted NI Availto Com Stockholders | $-3,514,900,000 | $-634,200,000 | $54,700,000 | $2,078,600,000 |
| Tax Provision | $-150,100,000 | $11,000,000 | $148,200,000 | $734,600,000 |
| Other Special Charges | $131,200,000 | $324,400,000 | $217,100,000 | $40,800,000 |
| Impairment Of Capital Assets | $2,936,800,000 | $321,000,000 | $580,100,000 | - |
| Restructuring And Mergern Acquisition | $-151,400,000 | $54,800,000 | $80,400,000 | $11,100,000 |
| Research And Development | $965,900,000 | $808,700,000 | $805,200,000 | $662,200,000 |
| Selling General And Administration | $3,794,100,000 | $4,104,600,000 | $4,070,000,000 | $4,179,100,000 |
Fetched: 2026-07-06
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-7,145,500,000 | $-7,568,700,000 | $-8,580,800,000 | $-11,960,600,000 |
| Total Assets | $37,193,100,000 | $41,500,900,000 | $47,685,500,000 | $50,022,200,000 |
| Total Non Current Assets | $27,403,900,000 | $31,980,200,000 | $34,709,400,000 | $39,386,800,000 |
| Other Non Current Assets | $785,600,000 | $754,000,000 | $821,100,000 | $753,300,000 |
| Non Current Deferred Assets | $1,061,200,000 | $753,000,000 | $692,900,000 | $1,225,400,000 |
| Non Current Deferred Taxes Assets | $1,061,200,000 | $753,000,000 | $692,900,000 | $925,900,000 |
| Investmentin Financial Assets | $815,000,000 | $1,349,800,000 | $1,142,000,000 | $1,091,400,000 |
| Goodwill And Other Intangible Assets | $21,856,800,000 | $26,204,200,000 | $29,048,200,000 | $33,032,900,000 |
| Other Intangible Assets | $15,102,100,000 | $17,070,900,000 | $19,181,100,000 | $22,607,100,000 |
| Current Assets | $9,789,200,000 | $9,520,700,000 | $12,976,100,000 | $10,635,400,000 |
| Other Current Assets | $136,200,000 | $387,200,000 | $271,000,000 | $328,400,000 |
| Current Deferred Assets | $568,300,000 | $526,600,000 | $1,068,500,000 | $747,200,000 |
| Current Deferred Taxes Assets | $568,300,000 | $526,600,000 | $747,300,000 | $747,200,000 |
| Prepaid Assets | $225,400,000 | $140,900,000 | $155,900,000 | $194,600,000 |
| Inventory | $3,999,200,000 | $3,854,100,000 | $3,469,700,000 | $3,519,500,000 |
| Receivables | $3,347,100,000 | $3,522,000,000 | $4,040,600,000 | $4,142,900,000 |
| Other Receivables | $453,700,000 | $546,000,000 | $876,600,000 | $570,700,000 |
| Taxes Receivable | $315,800,000 | $300,700,000 | $340,200,000 | $328,400,000 |
| Accounts Receivable | $2,577,600,000 | $2,675,300,000 | $2,823,800,000 | $3,243,800,000 |
| Allowance For Doubtful Accounts Receivable | $-136,000,000 | $-107,600,000 | $-118,800,000 | $-114,700,000 |
| Gross Accounts Receivable | $2,713,600,000 | $2,782,900,000 | $2,942,600,000 | $3,358,500,000 |
| Cash Cash Equivalents And Short Term Investments | $1,513,000,000 | $1,089,900,000 | $1,184,400,000 | $1,472,500,000 |
| Cash And Cash Equivalents | $1,322,400,000 | $734,800,000 | $991,900,000 | $1,259,900,000 |
| Assets Held For Sale Current | - | $0 | $2,786,000,000 | $230,300,000 |
| Debt | ||||
| Net Debt | $13,088,100,000 | $13,304,700,000 | $17,130,900,000 | $18,005,800,000 |
| Total Debt | $14,698,000,000 | $14,305,900,000 | $18,371,200,000 | $19,527,700,000 |
| Long Term Debt And Capital Lease Obligation | $12,658,700,000 | $14,218,200,000 | $16,353,500,000 | $18,196,600,000 |
| Long Term Debt | $12,480,600,000 | $14,038,900,000 | $16,188,100,000 | $18,015,200,000 |
| Current Debt And Capital Lease Obligation | $2,039,300,000 | $87,700,000 | $2,017,700,000 | $1,331,100,000 |
| Current Debt | $1,929,900,000 | $600,000 | $1,934,700,000 | $1,250,500,000 |
| Other Current Borrowings | $1,929,900,000 | $600,000 | $1,934,700,000 | $1,250,500,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $22,481,800,000 | $22,865,400,000 | $27,218,100,000 | $28,949,900,000 |
| Total Non Current Liabilities Net Minority Interest | $15,387,500,000 | $17,086,000,000 | $19,440,700,000 | $22,203,700,000 |
| Other Non Current Liabilities | $962,000,000 | $821,600,000 | $388,700,000 | $555,500,000 |
| Tradeand Other Payables Non Current | $332,600,000 | $341,900,000 | $399,300,000 | $414,600,000 |
| Non Current Deferred Liabilities | $892,000,000 | $1,107,900,000 | $1,735,700,000 | $2,432,000,000 |
| Non Current Deferred Taxes Liabilities | $892,000,000 | $1,107,900,000 | $1,735,700,000 | $2,432,000,000 |
| Current Liabilities | $7,094,300,000 | $5,779,400,000 | $7,777,400,000 | $6,746,200,000 |
| Other Current Liabilities | $989,900,000 | $1,340,500,000 | $1,406,700,000 | $1,238,100,000 |
| Payables And Accrued Expenses | $4,065,100,000 | $4,351,200,000 | $4,353,000,000 | $4,177,000,000 |
| Interest Payable | $52,900,000 | $49,900,000 | $66,800,000 | $80,200,000 |
| Payables | $1,878,100,000 | $2,046,400,000 | $2,165,000,000 | $2,068,700,000 |
| Other Payable | $460,400,000 | $498,400,000 | $556,800,000 | $608,600,000 |
| Total Tax Payable | $124,000,000 | $192,700,000 | $226,800,000 | $279,600,000 |
| Income Tax Payable | $124,000,000 | $192,700,000 | $226,800,000 | $279,600,000 |
| Accounts Payable | $1,293,700,000 | $1,355,300,000 | $1,381,400,000 | $1,158,000,000 |
| Minimum Pension Liabilities | - | - | - | $268,500,000 |
| Current Notes Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $14,711,300,000 | $18,635,500,000 | $20,467,400,000 | $21,072,300,000 |
| Total Equity Gross Minority Interest | $14,711,300,000 | $18,635,500,000 | $20,467,400,000 | $21,072,300,000 |
| Stockholders Equity | $14,711,300,000 | $18,635,500,000 | $20,467,400,000 | $21,072,300,000 |
| Gains Losses Not Affecting Retained Earnings | $-2,707,000,000 | $-3,212,900,000 | $-2,747,400,000 | $-2,761,200,000 |
| Other Equity Adjustments | $-2,707,000,000 | $-3,212,900,000 | $-2,747,400,000 | $-2,761,200,000 |
| Retained Earnings | $-388,300,000 | $3,418,800,000 | $4,639,700,000 | $5,175,600,000 |
| Long Term Equity Investment | - | - | - | $94,000,000 |
| Other | ||||
| Treasury Shares Number | $94,176,848 | $40,483,663 | $21,239,521 | - |
| Ordinary Shares Number | $1,151,215,081 | $1,193,647,828 | $1,200,754,970 | $1,213,793,231 |
| Share Issued | $1,245,391,929 | $1,234,131,491 | $1,221,994,491 | $1,213,793,231 |
| Tangible Book Value | $-7,145,500,000 | $-7,568,700,000 | $-8,580,800,000 | $-11,960,600,000 |
| Invested Capital | $29,121,800,000 | $32,675,000,000 | $38,590,200,000 | $40,338,000,000 |
| Working Capital | $2,694,900,000 | $3,741,300,000 | $5,198,700,000 | $3,889,200,000 |
| Capital Lease Obligations | $287,500,000 | $266,400,000 | $248,400,000 | $262,000,000 |
| Total Capitalization | $27,191,900,000 | $32,674,400,000 | $36,655,500,000 | $39,087,500,000 |
| Treasury Stock | $1,007,200,000 | $504,300,000 | $251,800,000 | $0 |
| Additional Paid In Capital | $18,801,300,000 | $18,921,600,000 | $18,814,700,000 | $18,645,800,000 |
| Capital Stock | $12,500,000 | $12,300,000 | $12,200,000 | $12,100,000 |
| Common Stock | $12,500,000 | $12,300,000 | $12,200,000 | $12,100,000 |
| Employee Benefits | $425,900,000 | $467,900,000 | $504,300,000 | $544,600,000 |
| Non Current Accrued Expenses | $116,300,000 | $128,500,000 | $59,200,000 | $60,400,000 |
| Long Term Capital Lease Obligation | $178,100,000 | $179,300,000 | $165,400,000 | $181,400,000 |
| Current Capital Lease Obligation | $109,400,000 | $87,100,000 | $83,000,000 | $80,600,000 |
| Current Accrued Expenses | $2,187,000,000 | $2,304,800,000 | $2,188,000,000 | $2,108,300,000 |
| Investments And Advances | $815,000,000 | $1,349,800,000 | $1,142,000,000 | $1,091,400,000 |
| Available For Sale Securities | $815,000,000 | $1,349,800,000 | $1,142,000,000 | $1,091,400,000 |
| Goodwill | $6,754,700,000 | $9,133,300,000 | $9,867,100,000 | $10,425,800,000 |
| Net PPE | $2,885,300,000 | $2,919,200,000 | $3,005,200,000 | $3,283,800,000 |
| Accumulated Depreciation | $-2,520,700,000 | $-2,203,200,000 | $-2,010,700,000 | $-2,059,300,000 |
| Gross PPE | $5,406,000,000 | $5,122,400,000 | $5,015,900,000 | $5,343,100,000 |
| Construction In Progress | $448,500,000 | $397,100,000 | $431,200,000 | $474,000,000 |
| Other Properties | $271,300,000 | $253,100,000 | $245,600,000 | $259,300,000 |
| Machinery Furniture Equipment | $3,043,400,000 | $2,894,700,000 | $2,774,500,000 | $2,936,700,000 |
| Buildings And Improvements | $1,527,900,000 | $1,464,300,000 | $1,444,400,000 | $1,539,700,000 |
| Land And Improvements | $114,900,000 | $113,200,000 | $120,200,000 | $133,400,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $2,085,100,000 | $1,980,900,000 | $2,135,900,000 | $2,192,600,000 |
| Work In Process | $491,700,000 | $527,300,000 | $602,100,000 | $755,400,000 |
| Raw Materials | $1,422,400,000 | $1,345,900,000 | $731,700,000 | $571,500,000 |
| Other Short Term Investments | $190,600,000 | $355,100,000 | $192,500,000 | $212,600,000 |
| Dueto Related Parties Current | - | - | $23,800,000 | $22,500,000 |
| Foreign Currency Translation Adjustments | - | - | - | $-3,385,900,000 |
| Unrealized Gain Loss | - | - | - | $-2,300,000 |
| Line Of Credit | - | - | - | $0 |
| Commercial Paper | - | - | - | $0 |
| Current Provisions | - | - | - | $888,800,000 |
Fetched: 2026-07-06
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $1,850,800,000 | $1,943,800,000 | $2,325,100,000 | $2,509,600,000 |
| Operating Activities | ||||
| Operating Cash Flow | $2,315,900,000 | $2,302,900,000 | $2,900,000,000 | $2,999,000,000 |
| Cash Flow From Continuing Operating Activities | $2,315,900,000 | $2,302,900,000 | $2,900,000,000 | $2,999,000,000 |
| Operating Gains Losses | $151,800,000 | $411,800,000 | $340,300,000 | $-1,707,700,000 |
| Investing Activities | ||||
| Capital Expenditure | $-465,100,000 | $-359,100,000 | $-574,900,000 | $-489,400,000 |
| Investing Cash Flow | $-427,700,000 | $1,800,700,000 | $-864,500,000 | $1,474,100,000 |
| Cash Flow From Continuing Investing Activities | $-427,700,000 | $1,800,700,000 | $-864,500,000 | $1,474,100,000 |
| Net Other Investing Changes | $2,500,000 | $2,507,100,000 | $364,100,000 | $1,950,000,000 |
| Capital Expenditure Reported | $-378,800,000 | $-326,000,000 | $-377,000,000 | $-406,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-500,500,000 | $-250,000,000 | $-250,000,000 | $0 |
| Issuance Of Capital Stock | $2,600,000 | $2,500,000 | $3,100,000 | $3,300,000 |
| Financing Cash Flow | $-1,293,900,000 | $-4,330,400,000 | $-2,301,900,000 | $-3,877,900,000 |
| Cash Flow From Continuing Financing Activities | $-1,293,900,000 | $-4,330,400,000 | $-2,301,900,000 | $-3,877,900,000 |
| Net Other Financing Charges | $-234,900,000 | $205,600,000 | $-229,800,000 | $-19,500,000 |
| Cash Dividends Paid | $-561,200,000 | $-574,800,000 | $-575,600,000 | $-581,600,000 |
| Common Stock Dividend Paid | $-561,200,000 | $-574,800,000 | $-575,600,000 | $-581,600,000 |
| Net Common Stock Issuance | $-497,900,000 | $-247,500,000 | $-246,900,000 | $3,300,000 |
| Common Stock Issuance | $2,600,000 | $2,500,000 | $3,100,000 | $3,300,000 |
| Other | ||||
| Repayment Of Debt | $-100,000 | $-3,713,700,000 | $-1,250,200,000 | $-3,662,500,000 |
| Issuance Of Debt | $0 | $0 | $300,000 | $1,875,600,000 |
| Interest Paid Supplemental Data | $492,600,000 | $561,100,000 | $611,600,000 | $642,500,000 |
| End Cash Position | $1,348,000,000 | $736,100,000 | $993,600,000 | $1,262,500,000 |
| Beginning Cash Position | $736,100,000 | $993,600,000 | $1,262,500,000 | $706,200,000 |
| Effect Of Exchange Rate Changes | $17,600,000 | $-30,700,000 | $-2,500,000 | $-38,900,000 |
| Changes In Cash | $594,300,000 | $-226,800,000 | $-266,400,000 | $595,200,000 |
| Common Stock Payments | $-500,500,000 | $-250,000,000 | $-250,000,000 | $0 |
| Net Issuance Payments Of Debt | $100,000 | $-3,713,700,000 | $-1,249,600,000 | $-3,280,100,000 |
| Net Short Term Debt Issuance | $200,000 | $0 | $300,000 | $-1,493,200,000 |
| Net Long Term Debt Issuance | $-100,000 | $-3,713,700,000 | $-1,249,900,000 | $-1,786,900,000 |
| Long Term Debt Payments | $-100,000 | $-3,713,700,000 | $-1,250,200,000 | $-3,662,500,000 |
| Long Term Debt Issuance | $0 | $0 | $300,000 | $1,875,600,000 |
| Net Investment Purchase And Sale | $0 | $0 | $0 | $-300,000 |
| Sale Of Investment | $23,900,000 | $26,000,000 | $26,300,000 | $29,900,000 |
| Purchase Of Investment | $-23,900,000 | $-26,000,000 | $-26,300,000 | $-30,200,000 |
| Net Business Purchase And Sale | $0 | $-350,000,000 | $-667,700,000 | $0 |
| Purchase Of Business | $0 | $-350,000,000 | $-667,700,000 | $0 |
| Net Intangibles Purchase And Sale | $-86,300,000 | $-33,100,000 | $-197,900,000 | $-83,400,000 |
| Purchase Of Intangibles | $-86,300,000 | $-33,100,000 | $-197,900,000 | $-83,400,000 |
| Net PPE Purchase And Sale | $34,900,000 | $2,700,000 | $14,000,000 | $13,800,000 |
| Sale Of PPE | $34,900,000 | $2,700,000 | $14,000,000 | $13,800,000 |
| Change In Working Capital | $-686,400,000 | $-318,600,000 | $-711,300,000 | $-922,600,000 |
| Change In Other Working Capital | $-746,600,000 | $68,700,000 | $-491,300,000 | $-593,000,000 |
| Change In Payables And Accrued Expense | $-168,000,000 | $36,000,000 | $314,700,000 | $170,200,000 |
| Change In Payable | $-168,000,000 | $36,000,000 | $314,700,000 | $170,200,000 |
| Change In Account Payable | $-168,000,000 | $36,000,000 | $314,700,000 | $170,200,000 |
| Change In Inventory | $-106,400,000 | $-723,400,000 | $-613,300,000 | $-259,500,000 |
| Change In Receivables | $334,600,000 | $300,100,000 | $78,600,000 | $-240,300,000 |
| Changes In Account Receivables | $334,600,000 | $300,100,000 | $78,600,000 | $-240,300,000 |
| Other Non Cash Items | $929,100,000 | $251,200,000 | $102,100,000 | $432,600,000 |
| Stock Based Compensation | $177,700,000 | $146,100,000 | $180,700,000 | $116,400,000 |
| Asset Impairment Charge | $2,936,800,000 | $321,000,000 | $580,100,000 | - |
| Deferred Tax | $-476,500,000 | $-767,600,000 | $-387,100,000 | $-25,900,000 |
| Deferred Income Tax | $-476,500,000 | $-767,600,000 | $-387,100,000 | $-25,900,000 |
| Depreciation Amortization Depletion | $2,798,300,000 | $2,893,200,000 | $2,740,500,000 | $3,027,600,000 |
| Depreciation And Amortization | $2,798,300,000 | $2,893,200,000 | $2,740,500,000 | $3,027,600,000 |
| Gain Loss On Sale Of PPE | $50,800,000 | $12,300,000 | $100,400,000 | $46,400,000 |
| Gain Loss On Sale Of Business | $101,000,000 | $399,500,000 | $239,900,000 | $-1,754,100,000 |
| Net Income From Continuing Operations | $-3,514,900,000 | $-634,200,000 | $54,700,000 | $2,078,600,000 |
| Income Tax Paid Supplemental Data | - | $514,000,000 | $570,900,000 | $735,200,000 |
| Earnings Losses From Equity Investments | - | - | $0 | $0 |
| Proceeds From Stock Option Exercised | - | - | - | $0 |
Fetched: 2026-07-06